Press Releases

 
Press Releases
Date Title and Summary View
Sep 24, 2015 SALT LAKE CITY, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced three poster presentations that will be featured at the 40th European Society for Medical Oncology (ESMO) meeting being held Sept. 25 to 29, 2015 in Vienna, Austria. The presentations i...
Sep 14, 2015 SALT LAKE CITY, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the Morgan Stanley Healthcare Conference at 9:20 a.m. EDT on September 18, 2015, at the Grand Hyatt in New York City, New York. The presentation will be availa...
Sep 9, 2015 SALT LAKE CITY, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today presented two posters on its myPlan® Lung Cancer prognostic test at the International Association for the Study of Lung Cancer (IASLC) 16TH World Conference on Lung Cancer being held in Denver, Colo. The first study showed that the myPlan Lung Cance...
Sep 2, 2015 SALT LAKE CITY, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in the personalized medicine industry with innovative, high-quality molecular diagnostics, today announced that it will host an Investor Day in New York City on Sept. 14, 2015. At the event, members of the Myriad executive management team will discus...
Sep 1, 2015 SALT LAKE CITY, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), announced that Elena Hitraya M.D., Ph.D., has joined the Company as the chief medical officer of Crescendo Bioscience, effective October 1, 2015. She will report to Bernie Tobin, president of Crescendo Bioscience...
Aug 13, 2015 SALT LAKE CITY, Aug. 13, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Noridian, the Medicare Administrative Contractor (MAC) for Myriad, has issued a final local coverage determination (LCD) for Prolaris®, Myriad's pioneering prognostic test for assessing the aggressiveness of prostate cancer. This decision...
Aug 11, 2015 Total Revenues of $189.9 Million Adjusted Diluted EPS of $0.41 and Diluted EPS of $0.26 myRisk™ Hereditary Cancer Panel Ended Fourth Quarter at 72 Percent ConversionCompany Provides Fiscal Year 2016 and Fiscal First-Quarter 2016 Financial Guidance SALT LAKE CITY, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today ...
Jul 29, 2015 SALT LAKE CITY, July 29, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will issue financial results for the fiscal fourth quarter and full year 2015 and provide a business update following the close of market on Tuesday, August 11, 2015. The Company also will host a conference call at 4:30 p.m. ET on Augus...
Jun 24, 2015 WASHINGTON and SALT LAKE CITY, June 24, 2015 (GLOBE NEWSWIRE) -- Chris4Life Colon Cancer Foundation, a Washington, D.C.-based national non-profit organization, and Myriad Genetics, a leader in personalized medicine, today announced their "What's Your History" family history week (June 24-30, 2015). "What's Your History" is an educational campaign t...
May 29, 2015 SALT LAKE CITY, May 29, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill. The myRisk Hereditary Cancer test assesses 25 g...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase